Litcius/Paper detail

Delta-tocotrienol disrupts PD-L1 glycosylation and reverses PD-L1-mediated immune suppression

Zhenou Sun, Xuan Ma, Chong Zhao, Lihong Fan, Shutao Yin, Hongbo Hu

2023Biomedicine & Pharmacotherapy12 citationsDOIOpen Access PDF

Abstract

PD-L1-mediated immune escape plays an important role in cancer development and progression. Targeting PD-L1 is consider to be an attractive approach for cancer treatment. PD-L1 is a heavily N-linked glycosylated protein, and the glycosylation of PD-L1 is essential for its ability to interact with its receptor PD-1 to mediate immune suppression. In the present study, we demonstrated for the first time that delta-tocotrienol (δ-T3) not any of the other forms of vitamin E was able to disrupt PD-L1 glycosylation mechanistically associated with the suppression of TCF4-STT3a/STT3b axis. The inhibition of PD-L1 glycosylation by δ-T3 resulted in the decrease of PD-L1 expression and its exosomal secretion, leading to the reduction of PD-L1 and PD-1 interaction, and reversing PD-L1-mediated immune suppression, which in turn contributed to the inhibitory effect on tumor growth. The findings of the present study provide a novel mechanistic interpretation for the superior anticancer activity of δ-T3 among 8 isomers of the vitamin E.

Topics & Concepts

GlycosylationImmune systemPD-L1ChemistryReceptorSecretionCancer researchCell biologyBiologyImmunologyBiochemistryImmunotherapyAtherosclerosis and Cardiovascular DiseasesMonoclonal and Polyclonal Antibodies ResearchGalectins and Cancer Biology
Delta-tocotrienol disrupts PD-L1 glycosylation and reverses PD-L1-mediated immune suppression | Litcius